Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures.

Dyall J, Nelson EA, DeWald LE, Guha R, Hart BJ, Zhou H, Postnikova E, Logue J, Vargas WM, Gross R, Michelotti J, Deiuliis N, Bennett RS, Crozier I, Holbrook MR, Morris PJ, Klumpp-Thomas C, McKnight C, Mierzwa T, Shinn P, Glass PJ, Johansen LM, Jahrling PB, Hensley LE, Olinger GG Jr, Thomas C, White JM.

J Infect Dis. 2018 Nov 22;218(suppl_5):S672-S678. doi: 10.1093/infdis/jiy304.


Off-Label Prescription of Psychopharmacological Drugs in Child and Adolescent Psychiatry.

Braüner JV, Johansen LM, Roesbjerg T, Pagsberg AK.

J Clin Psychopharmacol. 2016 Oct;36(5):500-7. doi: 10.1097/JCP.0000000000000559.


A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.

Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, Simmons JA, Grenier JM, Pierce LT, Pajouhesh H, Lehár J, Hensley LE, Glass PJ, White JM, Olinger GG.

Sci Transl Med. 2015 Jun 3;7(290):290ra89. doi: 10.1126/scitranslmed.aaa5597.


Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG Jr, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB.

Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. doi: 10.1128/AAC.03036-14. Epub 2014 May 19.


FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG.

Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471.


Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection.

Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM.

PLoS One. 2013;8(2):e56265. doi: 10.1371/journal.pone.0056265. Epub 2013 Feb 18. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/76780c06-ac81-48a3-8cce-509da6858fe5.


Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome.

Newman ZL, Sirianni N, Mawhinney C, Lee MS, Leppla SH, Moayeri M, Johansen LM.

Antimicrob Agents Chemother. 2011 Mar;55(3):1028-35. doi: 10.1128/AAC.00772-10. Epub 2010 Dec 13.


Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication.

Owens CM, Mawhinney C, Grenier JM, Altmeyer R, Lee MS, Borisy AA, Lehár J, Johansen LM.

Mol Syst Biol. 2010 Jun 8;6:375. doi: 10.1038/msb.2010.32.


Synergistic drug combinations tend to improve therapeutically relevant selectivity.

Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA.

Nat Biotechnol. 2009 Jul;27(7):659-66. doi: 10.1038/nbt.1549. Epub 2009 Jul 5. Erratum in: Nat Biotechnol. 2009 Sep;27(9):864.


Weak measurements with arbitrary probe states.

Johansen LM.

Phys Rev Lett. 2004 Sep 17;93(12):120402. Epub 2004 Sep 14.


The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells.

D'Alo' F, Johansen LM, Nelson EA, Radomska HS, Evans EK, Zhang P, Nerlov C, Tenen DG.

Blood. 2003 Nov 1;102(9):3163-71. Epub 2003 Jul 17.


EBNA2 and activated Notch induce expression of BATF.

Johansen LM, Deppmann CD, Erickson KD, Coffin WF 3rd, Thornton TM, Humphrey SE, Martin JM, Taparowsky EJ.

J Virol. 2003 May;77(10):6029-40.


Heterozygous PU.1 mutations are associated with acute myeloid leukemia.

Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG.

Blood. 2003 Mar 1;101(5):2074. No abstract available.


Heterozygous PU.1 mutations are associated with acute myeloid leukemia.

Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG.

Blood. 2002 Aug 1;100(3):998-1007.


c-Myc is a critical target for c/EBPalpha in granulopoiesis.

Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, Tenen DG.

Mol Cell Biol. 2001 Jun;21(11):3789-806.


Genomic organization of human B-ATF, a target for regulation by EBV and HTLV-1.

Meyer NP, Johansen LM, Tae HJ, Budde PP, Williams KL, Taparowsky EJ.

Mamm Genome. 1998 Oct;9(10):849-52. No abstract available.


IFP 35 forms complexes with B-ATF, a member of the AP1 family of transcription factors.

Wang X, Johansen LM, Tae HJ, Taparowsky EJ.

Biochem Biophys Res Commun. 1996 Dec 4;229(1):316-22.


B-ATF: a novel human bZIP protein that associates with members of the AP-1 transcription factor family.

Dorsey MJ, Tae HJ, Sollenberger KG, Mascarenhas NT, Johansen LM, Taparowsky EJ.

Oncogene. 1995 Dec 7;11(11):2255-65.


Supplemental Content

Loading ...
Support Center